Arecor Therapeutics (LSE:AREC) EV-to-EBIT : -4.33 (As of May. 21, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Arecor Therapeutics's Enterprise Value is £38.46 Mil. Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-8.89 Mil. Therefore, Arecor Therapeutics's EV-to-EBIT for today is -4.33.

The historical rank and industry rank for Arecor Therapeutics's EV-to-EBIT or its related term are showing as below:

LSE:AREC' s EV-to-EBIT Range Over the Past 10 Years
Min: -33.64 Med: -5.87 Max: -3.71
Current: -4.32

During the past 7 years, the highest EV-to-EBIT of Arecor Therapeutics was -3.71. The lowest was -33.64. And the median was -5.87.

LSE:AREC's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.09 vs LSE:AREC: -4.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Arecor Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was £49.48 Mil. Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-8.89 Mil. Arecor Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -17.96%.

Arecor Therapeutics EV-to-EBIT Historical Data

The historical data trend for Arecor Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics EV-to-EBIT Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-13.47

-5.80

-5.57

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial					-13.47	-	-5.80	-	-5.57

Competitive Comparison of Arecor Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Arecor Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arecor Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's EV-to-EBIT falls into.

Arecor Therapeutics EV-to-EBIT Calculation

Arecor Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	38.455	/	-8.886
	=	-4.33

Arecor Therapeutics's current Enterprise Value is £38.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-8.89 Mil.

Arecor Therapeutics (LSE:AREC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Arecor Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.886	/	49.480275
	=	-17.96 %

Arecor Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was £49.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-8.89 Mil.

Arecor Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.